TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Revelation Biosciences ( (REVB) ) has provided an announcement.
On December 3, 2025, Revelation Biosciences held a Special Meeting where stockholders approved the issuance of shares related to Class I Common Stock Warrants, extending their expiration to December 3, 2030. The company also provided a corporate update, highlighting the completion of a Phase 1b clinical study for Gemini in CKD patients, showcasing promising results in inflammation treatment. As they prepare for a meeting with the FDA, Revelation Biosciences plans to advance Gemini’s development for acute kidney injury treatment, aiming to start a Phase 2 or Phase 3 clinical study in 2026.
The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.
Spark’s Take on REVB Stock
According to Spark, TipRanks’ AI Analyst, REVB is a Underperform.
Revelation Biosciences is heavily challenged financially with no revenue and persistent losses. Technical indicators suggest bearish momentum, while valuation metrics reflect severe investor concerns, particularly due to the negative P/E ratio. The company’s reliance on external financing due to negative cash flows adds to the risk profile.
To see Spark’s full report on REVB stock, click here.
More about Revelation Biosciences
Revelation Biosciences operates in the biotechnology industry, focusing on developing treatments for inflammation-related conditions. Their primary product, Gemini, is aimed at rebalancing cellular inflammation, with a market focus on addressing both acute and chronic inflammation.
Average Trading Volume: 411,852
Technical Sentiment Signal: Sell
Current Market Cap: $5.61M
See more data about REVB stock on TipRanks’ Stock Analysis page.